In the Original Investigation titled “Life-Sustaining Treatment Decisions and Parent Caregiving Experiences for Children With Medical Complexity,” published June 11, 2026, there were errors in Table 3. For the subtheme titled, “Emotional-rational entanglement,” the second quote should have been attributed to a “39-year-old father of 7-year-old child with Goldenhar syndrome,” and the third quote should have been attributed to a “37-year-old mother of 4-year-old twins born prematurely.” In the abbreviations footnote, CMC should have been spelled out as “children with medical complexity.” This…
This cross-sectional study examines US state-level variation in days at home among older dually eligible Medicare beneficiaries with Alzheimer disease and related dementias (ADRD).
This cross-sectional study investigates trends in Escherichia coli and Klebsiella pneumoniae antimicrobial resistance in urinary samples from 6 African countries, 2010 to 2022.
This cohort study examines the association of P2Y purinergic receptor 12 (P2Y12) inhibitor antiplatelet use with stroke severity and in-hospital outcomes among patients with spontaneous intracerebral hemorrhage who used the antiplatelet therapy 7 days before hospitalization.
This cross-sectional study uses urine drug testing specimens to examine spatiotemporal trends in xylazine detection and relative concentration among samples positive for fentanyl from 2023 to 2025.
This diagnostic study investigates the ability of a previously trained artificial intelligence (AI) system to interpret blind sweep ultrasonography scans for gestational age estimation to generalize to new clinical environments.
This cohort study examines the association of the sustained availability of a dedicated high school health course with the prevalence of student-reported past 30-day substance use.
This cohort study compares sex-related differences in long-term all-cause and cause-specific mortality between male and female patients with cirrhosis.
Life Sciences sector attracts over £3 billion in new public-private investment in 12 months, reflecting international confidence in UK science and innovation.
FDA approval of Vera Therapeutics’ Trutakna makes it first in a new class of medicines designed to block two targets to treat immunoglobulin A nephropathy, an autoimmune disease that can progress to end-stage renal failure. Competition looms from Vertex Pharmaceuticals, on track to receive a November regulatory decision for a drug designed to block the same two proteins. The post Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval appeared first on MedCity News .
Pearl’s $110 million raise includes a $50 million equity investment led by Andreessen Horowitz with participation from Viking Global Investors, AlleyCorp and Ulysses Capital, as well as a $60 million debt facility led by Trinity Capital. The post Pearl Health Lands $110M to Support Value-Based Care for Medicare Patients appeared first on MedCity News .
Many startups and established companies focused on drug testing on human data in preclinical studies have been boosted by FDA’s move away from reliance on animal testing towards organoid, organ-on-a-chip, and other in silico technologies. A Connecticut startup believes whole-organ testing should be an essential part of this mix. The post Organ-on-a-chip, Organoids, but Drug Testing on Whole Organs? This Startup is Betting On It appeared first on MedCity News .
For high-risk patients with primary mitral valve regurgitation (MR), the novel Neonova transcatheter edge-to-edge repair (TEER) system was safe and effective, with a high rate of event-free survival and sustained clinical and echocardiographic improvements through two years, according to a prospective study published June 29 in JACC: Asia.
FDA’s final rule, Revising the National Drug Code Format and Drug Label Barcode Requirements, adopts a uniform, 12-digit format for the national drug code (NDC).
A joint editorial on behalf of the ACC, American Heart Association, European Society of Cardiology and World Heart Federation calls for a new era of equity-centered cardiovascular care designed to redefine prevention, optimize care delivery and ensure that all patients worldwide benefit equally from the promise of modern cardiovascular medicine.
About one in five patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events (MACE) over seven years of follow-up, according to SHaRe Registry research published July 8 in JACC.
Recent Actions and Updates From the American Diabetes Association mcarmody Wed, 07/08/2026 - 17:10 Organizational Updates Recent Actions and Updates From the American Diabetes Association Arlington, VA July 8, 2026 Since the CEO of the American Diabetes Association® (ADA), Charles “Chuck” Henderson, issued an apology —taking responsibility for missteps at the 2026 Scientific Sessions and personally apologizing to the five scientists by name—the ADA Executive team and Board of Directors have begun a comprehensive assessment of our practices, processes, and organizational approach…